Danaher (NYSE:DHR) Issues FY 2026 Earnings Guidance

Danaher (NYSE:DHR) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 8.350-8.550 for the period, compared to the consensus EPS estimate of 8.440. The company issued revenue guidance of -.

Danaher Stock Down 1.6%

Shares of NYSE:DHR opened at $180.65 on Friday. The firm has a fifty day moving average price of $181.15 and a two-hundred day moving average price of $204.96. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. Danaher has a one year low of $160.93 and a one year high of $242.80. The company has a market cap of $127.86 billion, a price-to-earnings ratio of 34.94, a PEG ratio of 2.45 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. The company had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. Danaher’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.88 earnings per share. Analysts anticipate that Danaher will post 8.43 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is currently 30.95%.

Analyst Ratings Changes

A number of brokerages recently weighed in on DHR. TD Cowen lowered their target price on shares of Danaher from $245.00 to $240.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. UBS Group lowered their target price on shares of Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Evercore raised their target price on shares of Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a research note on Tuesday, April 21st. Robert W. Baird lowered their target price on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Morgan Stanley lowered their target price on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $233.61.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Sivia Capital Partners LLC raised its stake in shares of Danaher by 6.3% during the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after acquiring an additional 119 shares in the last quarter. NCM Capital Management LLC purchased a new position in shares of Danaher during the third quarter worth approximately $226,000. Banco BTG Pactual S.A. purchased a new position in shares of Danaher during the third quarter worth approximately $225,000. Capital Planning Advisors LLC purchased a new position in shares of Danaher during the fourth quarter worth approximately $208,000. Finally, Pura Vida Investments LLC purchased a new position in shares of Danaher during the fourth quarter worth approximately $206,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.